Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail

Sarepta Therapeutics is seeking to convert the accelerated approval of its therapeutic exon-skippers for Duchenne muscular dystrophy to full despite the drugs’ failure to improve motor function in a confirmatory trial.